TLDR
Melbourne pet health startup Elita has closed a $1.9 million funding round backed by US firm Boost VC to fund Blueprint360, an at-home biomarker kit for dogs due before year's end. Four co-investors joined the round alongside a VetChat telehealth partnership giving owners round-the-clock vet access.
The raise
Melbourne pet health startup Elita has closed a $1.9 million funding round backed by US venture firm Boost VC, with Gandel Invest, Artesian's Female Leaders Fund, Touch Ventures and M8 Ventures joining as co-investors.[1] The capital goes toward finalising Blueprint360, an at-home biological test kit for dogs, and expanding the company's telehealth partnership with VetChat.
Elita framed the round's purpose around making every dog's biology visible and useful to the people who love them, per the company's announcement.[1] VetChat integration gives Blueprint subscribers 24-hour on-demand veterinary access through the app, adding a clinical layer to what Elita bills as a preventative care platform.[1]
Blueprint and Blueprint360
Elita's existing Blueprint platform combines a dog's biological data, clinical history and owner observations into a continuously updated health record.[3] Blueprint360 extends that record with at-home biomarker testing, giving owners a read on their dog's internal health without a clinic visit, with the kit due to ship before the end of 2026.[1]
Elita launched in June 2024 as Australia's first canine stem cell banking service before pivoting toward preventative health tracking.[2] Founder Paloma Newton said the stem cell offering was always oriented toward the longer arc of an individual animal's health. "When you bank your dog's stem cells with us, you're not just preparing for treatment, you're gaining access to your pet's unique biology and starting to build their individual health profile," Newton said.[2]
Elita enters a market where microbiome tests, DNA screening and telehealth rivals have multiplied as owners push to catch health issues earlier. Australia's companion animal health market is forecast to reach US $665.7 million in 2026, according to Grand View Research.[4] Bushletter could not independently verify Elita's product performance claims, which come from the company's own releases, and Blueprint360 remains on track for a launch before 31 December 2026.[1]
KEY TAKEAWAYS
SOURCES & CITATIONS
FREQUENTLY ASKED QUESTIONS
What is Elita's Blueprint360 product?
Who invested in Elita's funding round?
How big is Australia's companion animal health market?
Vikram Singh writes about banking. He follows where money actually moves, from the strategy set in head office to what changes on a customer's phone.
